Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 11/20 | 0.57 |
| ▸ | KDM5B | Q9UGL1 | 7/20 | 0.47 |
| ▸ | PLAT | P00750 | 2/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092404 | 0.99 | KDM5A (0.58) | KDM5AKDM5BPLATKDM5CKDM4C | |
| SCHEMBL17547797 | 0.98 | KDM5A (0.58) | KDM5AKDM5BPLATKDM5CKDM4C | |
| SCHEMBL17536040 | 0.92 | KDM5A (0.52) | KDM5AKDM5BPLATKDM5CKDM4C | |
| SCHEMBL17536042 | 0.92 | KDM5A (0.52) | KDM5AKDM5BPLATKDM5CKDM4C | |
| SCHEMBL16050617 | 0.91 | KDM5A (0.51) | KDM5AKDM5BPLATKDM5CKDM4C | |
| SCHEMBL16092337 | 0.91 | KDM5A (0.51) | KDM5AKDM5BPLAT | |
| SCHEMBL16092429 | 0.89 | KDM5A (0.50) | KDM5AKDM5BPLAT | |
| SCHEMBL16092545 | 0.89 | KDM5A (0.48) | KDM5AKDM5BPLATKDM5CKDM4C | |
| SCHEMBL16092380 | 0.89 | KDM5A (0.58) | KDM5AKDM5BPLATKDM5CKDM4C | |
| SCHEMBL16092334 | 0.88 | KDM5A (0.49) | KDM5AKDM5BPLATKDM5CKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | KDM5A 1/4885KDM5B 3/4885PLAT 4107/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | KDM5A 1/4885KDM5B 3/4885PLAT 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.